Sign up for investor news

Oncology Venture is a Scandinavian biotech company listed on Aktietorget as OV.ST.

Sign up to receive updates regarding:

  • Our pipeline of six targeted cancer drugs in phase 2 studies
  • Progress of the DRP® technology (the proprietary Drug Response Prediction technology we use)
  • Media coverage of our company (newspaper articles, tv interviews, etc.)



Subscribe for news from Oncology Venture

 

 
 

 





 

Pipeline overview

  • TKI, an oral tyrosine kinase inhibitor product, licensed from Novartis. In previous clinical trials, it has been used to treat kidney cancer.
  • LiPlaCis, a drug used to treat hard-to-treat breast cancer patients in ongoing phase 2 studies
  • 2X-121, an inhibitor of a key enzyme involved in DNA damage repair in cancer cells. The drug has been tested with a number of cancers, including ovarian and breast cancer.
  • APO010, a drug ready to enter a focused phase 2 trial, with breast cancer, ovarian cancer or multiple myeloma.
  • Irofulven, a drug having shown results in treatments of prostate and ovarian cancer patients.
  • 2X-111, the anticancer drug in 2X-111, doxorubicin, has shown encouraging signs of anti-tumor activity in, amongst others, metastatic breast cancer and glioblastoma.
  • 2X-131, a drug where the final terms are still being negotiated.